Sign in

    Avantika Joshi

    Research Analyst at Mizuho Securities

    Avantika Joshi is an Equity Research Associate at Mizuho Securities USA LLC, specializing in financial analysis and investment strategies for investment banking clients. She covers sectors including consumer, energy, financial institutions, healthcare, industrials, real estate, and technology, supporting research across multiple major publicly traded companies within these industries. Since joining Mizuho Securities in July 2022, she has built her career with previous analyst roles at Berenberg Capital Markets LLC from 2020 to 2022 and Independence Blue Cross LLC from 2017 to 2018. Joshi holds an undergraduate degree from Drexel University (2020), and is expected to maintain FINRA registration typical for equity research associates, reflecting her professional standing in securities analysis.

    Avantika Joshi's questions to Immunocore Holdings (IMCR) leadership

    Avantika Joshi's questions to Immunocore Holdings (IMCR) leadership • Q2 2024

    Question

    Avantika Joshi from Mizuho Securities asked if Immunocore is still evaluating brenetafusp in tumors beyond melanoma, ovarian, and lung, and whether early-stage assets would utilize basket studies or focus on specific tumors.

    Answer

    CFO Brian Di Donato confirmed interest in other tumors like endometrial but stated the team's current focus is on the three main programs. Mohammed Dar, an executive, explained that for early-stage PRAME assets, learnings are being applied from the lead program, and the trials are designed to enroll patients across multiple tumor types where PRAME is expressed.

    Ask Fintool Equity Research AI

    Avantika Joshi's questions to Immunocore Holdings (IMCR) leadership • Q2 2024

    Question

    Avantika Joshi from Mizuho Securities asked if Immunocore is exploring brenetafusp in tumors beyond the main three and whether the early-stage assets are being studied in basket trials or specific tumors.

    Answer

    Executive Brian Di Donato confirmed interest in other tumors like endometrial but said the team is focused on the three priority indications. Mohammed Dar, an executive, explained that learnings from the main PRAME program allow the newer trials to enroll multiple patient types where PRAME is expressed.

    Ask Fintool Equity Research AI

    Avantika Joshi's questions to BioXcel Therapeutics (BTAI) leadership

    Avantika Joshi's questions to BioXcel Therapeutics (BTAI) leadership • Q1 2024

    Question

    Avantika Joshi, on for Graig Suvannavejh, asked about the company's trial priorities between TRANQUILITY In-Care and SERENITY At-Home, and whether the studies would be run concurrently.

    Answer

    Executive Vimal Mehta stated that strategically, the preference is to run both trials in parallel. He characterized SERENITY as a nearer-term opportunity for label expansion and TRANQUILITY as a larger, longer-term growth driver. He noted that if necessary, they would decide whether to prioritize one or adopt a stepwise approach.

    Ask Fintool Equity Research AI

    Avantika Joshi's questions to Rain Enhancement Technologies Holdco (RAIN) leadership

    Avantika Joshi's questions to Rain Enhancement Technologies Holdco (RAIN) leadership • Q2 2023

    Question

    Avantika Joshi from Mizuho Securities asked how management weighs the benefits of acquiring a new asset against other corporate strategies, such as a reverse merger.

    Answer

    CEO Avanish Vellanki explained that the company evaluates all options based on their attractiveness and actionability. He noted that if an opportunity allows Rain to add value with its existing resources, it becomes a more attractive path. He emphasized the current biotech climate presents a multitude of such opportunities.

    Ask Fintool Equity Research AI

    Avantika Joshi's questions to Rain Enhancement Technologies Holdco (RAIN) leadership • Q1 2023

    Question

    Avantika Joshi of Mizuho Securities asked if MANTRA-2 clinical sites outside the U.S. were open, requested timeline guidance for the next MANTRA-2 data readout, and questioned the implications for MANTRA-2 and MANTRA-4 if the MANTRA trial were to fail.

    Answer

    CEO Avanish Vellanki provided no new guidance on MANTRA-2 data timelines and declined to speculate on scenarios following a potential MANTRA trial failure. CMO Richard Bryce confirmed they are on track to add up to 20 ex-U.S. sites in the next 2-3 months, focusing on centers with genomic screening capabilities.

    Ask Fintool Equity Research AI